COMMUNIQUÉS West-GlobeNewswire

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
31/01/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31/01/2024
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31/01/2024
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to March 3, 2024
31/01/2024
MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
31/01/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
DLH Reports Fiscal 2024 First Quarter Results
31/01/2024
Further Debt Reduction and Strong Start to Fiscal Year ATLANTA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, [...]
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31/01/2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, [...]
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31/01/2024
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
31/01/2024
PARIS and CAMBRIDGE, Mass., 31 janv. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/01/2024
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need [...]
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31/01/2024
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that [...]
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
31/01/2024
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31/01/2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement [...]
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31/01/2024
SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
31/01/2024
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. [...]
Compass Pathways to participate in upcoming Oppenheimer investor conference
31/01/2024
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that [...]
AHG Announces Plan to Acquire Online Clinic
31/01/2024
QINGDAO CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) ( "Akso Health," "the Company," or "we") today announced its plan to make an equity investment in Deyihui, an online clinic based in China [...]
Merus annonce la tenue d’une série de conférences auprès des investisseurs
31/01/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 janv. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur [...]
SAFE - Lettre aux actionnaires
31/01/2024
Lettre aux actionnaires N°1 - Janvier 2024 La renaissance du Groupe SAFE Madame, Monsieur, Chers actionnaires, Permettez-nous de vous adresser nos meilleurs vœux pour cette nouvelle année. 2023 a été une année [...]

Pages